Commit To Purchase Acceleron Pharma At $30, Earn 16.7% Annualized Using Options
at The Street - Wed Dec 24, 11:20AM CST
Investors considering a purchase of Acceleron Pharma, Inc. shares, but tentative about paying the going market price of $39.00/share, might benefit from considering selling puts among the alternative strategies at their disposal.
XLRN: 38.80 (+0.80)
Myelofibrosis - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/5dgl3c/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - AstraZeneca PLC - Eli Lilly and Company - Gilead Sciences, Inc. - Novartis AG - Cell Therapeutics, Inc. - Celgene Corporation - Incyte Corporation - Geron Corporation - MEI Pharma, Inc. - Threshold Pharmaceuticals, Inc. - Acceleron Pharma, Inc. - Promedior, Inc. For more information visit http://www.researchandmarkets.com/research/5d...lofibrosis
GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), INCY: 71.57 (+1.99), AZN: 70.44 (+0.26), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), NVS: 93.91 (+0.66), MEIP: 3.90 (+0.11), CELGZ: 3.34 (-0.01), XLRN: 38.80 (+0.80)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Acceleron Pharma Added to NASDAQ Biotechnology Index
Business Wire - Mon Dec 15, 7:00AM CST
Acceleron Pharma Inc. (NASDAQ: XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it has been selected for addition to the NASDAQ Biotechnology Index(R) (NASDAQ: NBI), effective Monday, December 22, 2014.
XLRN: 38.80 (+0.80)
Acceleron Pharma elects Dr. Francois Nader to its board
M2 - Mon Dec 15, 6:22AM CST
Biopharmaceutical company Acceleron Pharma (NasdaqGM:XLRN) disclosed on Friday the addition of Dr. Francois Nader, M.D., M.B.A, to its board of directors.
XLRN: 38.80 (+0.80)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Acceleron Pharma Appoints Dr. Francois Nader to its Board of Directors
Business Wire - Fri Dec 12, 6:30AM CST
Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced the appointment of Francois Nader, M.D., M.B.A, to its Board of Directors.
XLRN: 38.80 (+0.80)
InsiderInsights.com Daily Round Up 12/10/14: PSEC, TWI, SGEN, ATLS
InsiderInsights - at Seeking Alpha - Thu Dec 11, 12:18AM CST
TRVN: 5.38 (-0.37), HSGX: 10.51 (-0.46), VR: 41.51 (+0.19), LBTYK: 49.10 (+0.05), ATLS: 30.37 (-0.07), UHS: 111.87 (+0.99), CLH: 49.40 (-0.60), WMS: 23.00 (+0.28), ALEX: 40.09 (+0.38), CDW: 35.75 (+0.14), BABY: 36.45 (+1.14), PRSS: 2.42 (-0.01), SGEN: 31.10 (-0.14), CO: 4.40 (+0.05), HBI: 110.93 (-0.07), TWI: 10.92 (-0.20), HSIC: 137.87 (+0.15), PSEC: 8.59 (-0.02), XLRN: 38.80 (+0.80)
Luspatercept Data on Myelodysplastic Syndromes Selected for "Best of ASH" by the American Society of Hematology
Business Wire - Wed Dec 10, 6:30AM CST
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that the presentation of data from the luspatercept phase 2 clinical trial in patients with lower risk myelodysplastic syndromes (MDS) was selected for "Best of ASH" at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition. The "Best of ASH" session, led by the 2014 Annual Meeting Scientific Program Co-Chairs, highlighted twenty-four of the top hematology breakthroughs selected from the meeting's more than 4,000 abstract presentations.
XLRN: 38.80 (+0.80)
Acceleron Pharma, Inc. (XLRN) in Focus: Stock Soars 13.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 8:21AM CST
Acceleron Pharma, Inc. (XLRN) was a big mover last session, as the company saw its shares rise by around 14% on the day.
BIIB: 340.89 (+5.13), ANIP: 55.24 (+1.79), AFFX: 9.80 (+0.05), XLRN: 38.80 (+0.80)
New Data in Myelodysplastic Syndromes Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition
Business Wire - Mon Dec 08, 1:18PM CST
Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced preliminary data from ongoing phase 2 clinical trials in patients with lower risk myelodysplastic syndromes (MDS) at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition. In his oral presentation, Dr. Uwe Platzbecker showed that patients with lower risk MDS treated with luspatercept achieved increased hemoglobin levels and transfusion independence. In a separate poster presentation, Dr. Rami Komrokji showed that lower risk MDS patients who were treated with sotatercept also achieved increased hemoglobin levels and transfusion independence. Celgene and Acceleron are jointly developing luspatercept and sotatercept.
XLRN: 38.80 (+0.80), CELG: 109.60 (+3.48), CELGZ: 3.34 (-0.01)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 11:45AM CST
LGCY: 11.86 (-0.49), PFIE: 2.38 (-0.12), MCEP: 6.07 (-0.12), MDGN: 5.19 (-0.02), LQDT: 8.19 (-0.19), AXPW: 1.00 (-0.04), PRTK: 37.70 (+1.30), BSI: 2.62 (-0.08), DRIV: 24.49 (+0.09), CBST: 100.29 (-0.09), QTWW: 2.39 (-0.01), CALA: 22.33 (+1.16), MPO: 1.63 (-0.05), SNSS: 2.48 (-0.03), CTP: 14.57 (-0.18), LPX: 16.74 (+0.27), SAEX: 4.60 (+0.05), DRYS: 1.20 (-0.04), VPCO: 1.30 (-0.01), XLRN: 38.80 (+0.80)
Encouraging results for luspatercept in Phase 2
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 10:51AM CST
CELG: 109.60 (+3.48), XLRN: 38.80 (+0.80)
The 7 Most Important Drug-Stock Lessons From This Weekend's Blood Cancer Meeting
at The Street - Mon Dec 08, 6:15AM CST
Here's what I learned about biotech and drug stocks after covering the American Society of Hematology annual meeting.
BLUE: 88.76 (+3.23), SGEN: 31.10 (-0.14), MRK: 57.46 (+0.25), SNSS: 2.48 (-0.03), AGIO: 109.67 (+2.45), BMY: 59.15 (-0.01), XLRN: 38.80 (+0.80), NVS: 93.91 (+0.66), CELG: 109.60 (+3.48)
Acceleron Drugs Reduce Anemia Caused by Rare Blood Disorders
at The Street - Sun Dec 07, 2:33PM CST
Celgene has worldwide clinical development and marketing rights to the two Acceleron drugs, known as luspatercept and sotatercept.
BLUE: 88.76 (+3.23), AMGN: 160.67 (+3.15), XLRN: 38.80 (+0.80), CELG: 109.60 (+3.48)
3 Large Cap Biotech Stocks That Could Pay Dividends, But Won't
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 07, 11:39AM CST
Source: Flickr user Tax Credits Dividend paying companies are a key part of any investor's long-haul portfolio, but investors that lean toward high growth industries like biotechnology have few dividend-paying options. Despite multibillion...
BIIB: 340.89 (+5.13), ISIS: 59.49 (+1.88), OMED: 20.92 (+0.76), GILD: 91.29 (+1.84), TEVA: 57.09 (+0.33), EPZM: 17.71 (+0.01), AGIO: 109.67 (+2.45), SNY: 46.35 (+0.50), FOLD: 7.94 (+0.06), XLRN: 38.80 (+0.80), NVS: 93.91 (+0.66), CELG: 109.60 (+3.48)
New Data from Luspatercept Phase 2 Clinical Trial in Beta-Thalassemia Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition
Business Wire - Sun Dec 07, 11:00AM CST
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the presentation of preliminary data from the luspatercept phase 2 clinical trial in patients with beta-thalassemia at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition. This presentation was one of four selected by ASH to be highlighted in this morning's press briefing on emerging anemia treatments. Dr. Antonio Piga will present the full set of data in an oral session, showing that luspatercept increased hemoglobin levels, reduced transfusion burden, and improved measures of iron overload in beta-thalassemia patients. Celgene and Acceleron are jointly developing luspatercept.
CELG: 109.60 (+3.48), CELGZ: 3.34 (-0.01), XLRN: 38.80 (+0.80)
Will Acceleron (XLRN) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 8:24AM CST
Will Acceleron (XLRN) Continue to Surge Higher?
XLRN: 38.80 (+0.80)
Hepatocellular Carcinoma - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8fjnjx/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4SC - AbbVie - Acceleron Pharma - ACROVIS biostructures - Alfact Innovation - Alnylam - Amgen - AndroScienceration - ArQule - Arrowhead Researchration - Astex - AstraZeneca - Avidin Ltd - Bayer - Bio-Cancer Treatment - Blueprint Medicines - Boehringer Ingelheim - Boston Biomedical - Can-Fite BioPharma - CASI - CCRP Therapeutics - Celgeneration - Celsionration - China Medical System Holdings - Chroma Therapeutics - CrystalGenomics - CytRxration - Delcath Systems - Dicerna - Digna Biotech S.L. - Eisai. - Eli Lilly and Company - Endocyte - Exelixis - F. Hoffmann-La Roche - Gamida Cell - Geneluxration - Genoscience Pharma - GenSpera - GlaxoSmithKline - Green Cross Cellration - Immune Network - Immunicum AB - Immunomedics - Immunovative Therapies - Immuron - In Cell Art - Incuron LLC - Intezyne Inc - KAEL-GemVax. - KAHR medical - Kowa Company - La Jolla Pharmaceutical Company - Ligand - Lixte Biotechnology Holdings - MaxCyte - Merck KGaA - Millennium - MolMed S.p.A. - MultiCell Technologies - NeoStem - Nerviano Medical Sciences - Novartis - Nymox Pharmaceuticalration - Omerosration - Oncolys BioPharma - OncoTherapy Science - Ono Pharmaceutical. - Onxeo SA - Otsuka Holdings. - Panacea - Peregrine - Pfizer - PharmaEssentiaration - PhaseRx - Polaris - Priaxon - Progen - Provecs Medical - Provectus Biopharmaceuticals - Quantum - Raptor - Regulus Therapeutics - Rigontec - Santaris Pharma A/S - Sevion Therapeutics - Shanghai Sunway Biotech - Shenogen Pharma - Silence Therapeutics - SillaJen Co. - Simcere Pharmaceutical - Solasia Pharma K.K. - Synta - Taiwan Liposome Company - Tekmira - Therametrics holding - Therapure Biopharma - THERAVECTYS SA - Threshold - Toko Pharmaceutical Industries. - TRACON - Vaxon Biotech - Vertexrporated - Vicus Therapeutics LLC - Virttu Biologics For more information visit http://www.researchandmarkets.com/research/8f...tocellular
IMMU: 4.41 (+0.13), AMGN: 160.67 (+3.15), RGLS: 14.78 (+0.24), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), PVCT: 0.85 (-0.02), CANF: 3.70 (+0.01), DCTH: 1.36 (+0.01), NVS: 93.91 (+0.66), XLRN: 38.80 (+0.80)